Novacea gained access to Kudos Pharmaceuticals’ anticancer agent. AQ4N (banoxantrone) is currently in Phase I evalution in patients with advanced oesophageal cancer.
"The extensive preclinical and clinical data generated to date gives us confidence in the significant opportunity AQ4N presents as an anticancer agent in multiple tumor types and hematological malignancies," states John P. Walker, chairman and interim CEO of Novacea.
As part of the agreement, Novacea will acquire an exclusive license and worldwide development and commercialization rights for the candidate. Kudos anticipates it will complete patient recruitment for its ongoing Phase I trials with AQ4N around the middle of 2007.
Kudos obtained a worldwide license for AQ4N from BTG in March 2002 and subsequently licensed the North American rights to Novacea in December 2003.